UK study finds COVID-19 mRNA vaccines have the greatest booster impact – .

0
11
UK study finds COVID-19 mRNA vaccines have the greatest booster impact – .


  • Publication of the data underlying the recall decision in the United Kingdom
  • Pfizer and Moderna give large antibodies and stimulate T cells
  • Broad T cell responses give hope for protection against variants

LONDON, December 2 (Reuters) – COVID-19 vaccines manufactured by Pfizer (PFE.N) and Moderna (MRNA.O) that use mRNA technology provide the biggest boost in antibody levels when they are given 10 to 12 weeks after the second dose, a British study published on Thursday found.

The ‘COV-Boost’ study was cited by UK officials when they announced Pfizer and Moderna were preferred for use in the country’s recall campaign, but the data has only been made public now. Read more

The study found that six of the seven boosters looked at enhanced immunity after the initial vaccination with the Pfizer-BioNTech vaccine, while all seven increased immunity when given after two doses of the AstraZeneca vaccine (AZN. THE).

Register now for FREE and unlimited access to reuters.com

“A third dose will be effective for many vaccines we have tested and in many different combinations,” Professor Saul Faust, an immunologist at the University of Southampton and head of the trial, told reporters.

The study found that a full or half dose of Pfizer or a full dose of Moderna provided a very effective boost in antibody and T cell levels, whether the person had initially received Pfizer or AstraZeneca.

When AstraZeneca, Novavax, Johnson & Johnson, and Curevac were given as boosters, they increased antibody levels for either of the original vaccines, albeit to a lesser extent. However, while Valneva stimulated antibodies in people initially vaccinated with AstraZeneca, it did not stimulate Pfizer.

The study found that the booster shots also helped generate a broad T-cell response against beta and delta variants, which could play a key role in long-term protection.

“T cells (response) appear to be larger against all variant strains, giving us hope that a variant strain of the virus could be manipulated, certainly hospitalization and death, if not prevention of infection, by current vaccines, ”Faust said.

The study predates the spread of the omicron variant of concern, but Faust said he shared samples with the UK Health Safety Agency to generate data on Omicron as well.

Register now for FREE and unlimited access to reuters.com

Reportage by Listair Smout; Montage by Bernadette Baum

Our Standards: Thomson Reuters Trust Principles.

LEAVE A REPLY

Please enter your comment!
Please enter your name here